Igyxos, a Nouzilly, France-based biotechnology company specializing in the development of a new treatment for female and male infertility, raised €7.5m in Series A funding.
– Bpifrance, via the Accelerate Biotechnologies Santé Fund managed by Bpifrance in the framework of the Investments for the Future Program,
– Go Capital Amorçage II and Loire Valley Invest Funds managed by Go Capital, and
– the Fonds Emergence Innovation II managed by Sofimac Innovation.
The company intends to use the funds to finance the development of its drug candidate until proof of concept in human clinic.
Led by Pierre-Henry Longeray, CEO, previously Chief Executive Officer of Merck Biopharma France, and Marie-Christine Maurel, founder and CSO, Igyxos is developing a “First-In-Class” treatment, based on the use of monoclonal antibodies, to fight against female and male infertility. By developing a monoclonal antibody capable of potentiating the bioactivity of endogenous and exogenous gonadotropins, Igyxos aims to improve the therapeutic management of men and women suffering from infertility.